Utah Medical Products (UTMD) has just opened Q1 2026 reporting season with a backdrop of steady recent financials, capped by Q4 2025 revenue of about US$9.0 million and basic EPS of roughly US$0.80, supported by trailing 12 month totals of US$38.5 million in revenue and EPS of about US$3.48. Over the past few quarters, the company has seen quarterly revenue range between roughly US$9.0 million and US$10.0 million, with basic EPS moving between about US$0.80 and US$1.02. Trailing 12 month net income sits near US$11.3 million, and a recent net margin of 29.3% points to compressed but still solid profitability. Against that setup, investors will be weighing Q1 2026 through the lens of how far margins have pulled back and what that implies for earnings resilience.

See our full analysis for Utah Medical Products.

With the latest numbers on the table, the next step is to see how they line up against the prevailing stories around Utah Medical Products, highlighting where the data supports those narratives and where it pushes back.

Margins Ease Back From 33.9% To 29.3%

• Over the last 12 months, UTMD recorded a net profit margin of 29.3%, compared with 33.9% a year earlier, alongside trailing 12 month net income of US$11.3 million on US$38.5 million of revenue.
• Bears focus on a 1.7% annual earnings decline over five years and the recent drop in trailing margin, yet that same period still shows double digit profitability, which creates some tension for a purely bearish view:
  • The trailing 12 month EPS of about US$3.48 sits below the US$3.96 and US$4.28 levels seen in earlier trailing periods, which supports the concern about earnings pressure.
  • At the same time, a 29.3% net margin on US$38.5 million of revenue indicates the business is still converting a sizeable share of sales into profit, rather than showing a collapse in economics.

Five Year Earnings Drift Vs 19x P/E

• UTMD's trailing P/E of 19x sits above the 16.4x peer average but below the 25.4x US Medical Equipment industry level, while earnings have declined about 1.7% per year over the past five years.
• Critics highlight the multi year earnings decline as a reason to question paying a 19x P/E, and the numbers give them some support while also adding context:
  • Trailing 12 month net income has eased from about US$15.3 million at the 2024 Q3 mark to US$11.3 million by 2025 Q4, which lines up with concerns about pressure on profitability.
  • However, the P/E still sits below the broader industry’s 25.4x, so the market is not valuing UTMD at a clear premium despite that earnings record.

DCF Fair Value Of US$116.24 Vs US$67.17 Price

• The supplied DCF fair value of US$116.24 stands well above the current share price of US$67.17, implying about a 42% gap, alongside a 1.85% dividend yield on trailing figures.
• Supporters of a more bullish stance point to this valuation gap, and the earnings record gives them both a positive and a cautionary data point:
  • The stock price of US$67.17 compared with a DCF fair value of US$116.24 suggests the market is pricing in weaker cash flows than the model, even though trailing net income is still US$11.3 million.
  • Yet, with trailing 12 month revenue slipping from about US$44.1 million at 2024 Q3 to US$38.5 million at 2025 Q4, the same data set reminds investors that any perceived upside rests on reversing or stabilising that earnings and margin trend.

To see how other investors are interpreting these margin trends, valuation signals, and earnings pressures together, check out the Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Utah Medical Products's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Feeling torn between the margin pressure and the valuation gap? Take a closer look at the underlying figures now and weigh both sides of the story with the 2 key rewards and 1 important warning sign

See What Else Is Out There

Utah Medical Products is dealing with easing margins, a trailing earnings drift and a 19x P/E set against softer recent revenue and profit figures.

If that mix of earnings pressure and valuation leaves you cautious, compare it with companies that screen as attractively priced with stronger fundamentals using the 56 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.